Industry
Biotechnology
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 3:27 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 12:31 pm
Portfolio Pulse from Benzinga Newsdesk
December 14, 2023 | 1:58 pm
Portfolio Pulse from Benzinga Insights
November 15, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
November 09, 2023 | 6:53 pm
Portfolio Pulse from Benzinga Newsdesk
November 08, 2023 | 10:09 pm
Portfolio Pulse from Benzinga Insights
September 21, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Insights
August 10, 2023 | 5:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.